LENVIMA® for first-line unresectable hepatocellular carcinoma
Mechanism of action (MOA) of LENVIMA
LENVIMA is thought to block receptors required for tumor growth and blood vessel development1
- LENVIMA is a kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor receptors (VEGFR): VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4)2
- LENVIMA inhibits other kinases (including FGFR1, 2, 3, and 4; PDGFRα, KIT, and RET) that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression, in addition to their normal cellular functions2
VEGF=vascular endothelial growth factor; FGF=fibroblast growth factor; VEGFR=vascular endothelial growth factor; FGFR=fibroblast growth factor receptor; FLT=Fms-related tyrosine; KDR=kinase insert domain receptor; PDGFRα=platelet-derived growth factor receptor alpha; RET=rearranged during transfection.